These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 36036563)

  • 1. An EGFR-mutant lung adenocarcinoma that transformed into small-cell lung cancer. A case report.
    Chowaniecova G; Berzinec P; Kosturiakova G; Plank L; Farkasova A; Sekeresova M; Juskanic D; Ondrus D
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Dec; 166(4):451-454. PubMed ID: 36036563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous Acquisition of T790M Mutation and SCLC Transformation during Targeted Therapy in EGFR-Mutated Lung Adenocarcinoma: A Rare Case Report.
    Yazaki T; Kimoto M; Minagawa A; Maruno T; Yamanaka M; Sonehara K; Hama M; Nakamura T; Kanda S; Hanaoka M; Hachiya T
    Am J Case Rep; 2024 Jun; 25():e943466. PubMed ID: 38822519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming T790M mutant small cell lung cancer with the third-generation EGFR-TKI osimertinib.
    Tang K; Jiang N; Kuang Y; He Q; Li S; Luo J; Jiang W; Chen Y; Sun Y; Chen L; Chen Y; Zhu J; Cui Y; Wan H; Ke Z
    Thorac Cancer; 2019 Feb; 10(2):359-364. PubMed ID: 30521113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transformation of NSCLC to SCLC after 1st- and 3rd-generation EGFR-TKI resistance and response to EP regimen and erlotinib: 2 CARE-compliant case reports.
    Lai L; Meng W; Wei J; Zhang X; Tan Z; Lu Y; Hou E
    Medicine (Baltimore); 2021 Mar; 100(10):e25046. PubMed ID: 33725888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histological transformation of lung adenocarcinoma to small cell lung cancer with mutant C797S conferring acquired resistance to osimertinib.
    Ren X; Cai X; Li J; Zhang X; Yu J; Song X; Zhang H; Song X
    J Int Med Res; 2020 Jun; 48(6):300060520927918. PubMed ID: 32600081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
    Marcoux N; Gettinger SN; O'Kane G; Arbour KC; Neal JW; Husain H; Evans TL; Brahmer JR; Muzikansky A; Bonomi PD; Del Prete S; Wurtz A; Farago AF; Dias-Santagata D; Mino-Kenudson M; Reckamp KL; Yu HA; Wakelee HA; Shepherd FA; Piotrowska Z; Sequist LV
    J Clin Oncol; 2019 Feb; 37(4):278-285. PubMed ID: 30550363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential small cell transformation and T790M mutation in an epidermal growth factor-mutant lung adenocarcinoma: A rare occurrence with significant management implications.
    Shastri M; Gupta P; Gupta N; Singh N; Bal A; Srinivasan R; Khosla D
    Cytopathology; 2022 Nov; 33(6):732-737. PubMed ID: 35867808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transformation or tumor heterogeneity: Mutations in EGFR, SOX2, TP53, and RB1 persist in the histological rapid conversion from lung adenocarcinoma to small-cell lung cancer.
    Hao L; Chen H; Wang L; Zhou H; Zhang Z; Han J; Hou J; Zhu Y; Zhang H; Wang Q
    Thorac Cancer; 2023 Apr; 14(11):1036-1041. PubMed ID: 36810856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneity or transformation? A whack-a-mole case of EGFR-mutant lung adenocarcinoma and small cell carcinoma: A case report.
    Ninomaru T; Hata A; Hara S; Komatsu M
    Thorac Cancer; 2022 Aug; 13(16):2394-2397. PubMed ID: 35793695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
    Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
    Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study.
    Wang W; Xu C; Chen H; Jia J; Wang L; Feng H; Wang H; Song Z; Yang N; Zhang Y
    Lung Cancer; 2021 May; 155():20-27. PubMed ID: 33714778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of 3rd generation TKI in patients with EGFR mutation lung adenocarcinoma with bone metastases: A review of 3 case reports and literature.
    Guo Q; Feng W; Hu S; Ye J; Wang S; Su L; Zhang Y; Zhang D; Zhang W; Xu J; Wei Y
    Medicine (Baltimore); 2023 Aug; 102(34):e34545. PubMed ID: 37653755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR-Mutant SCLC Exhibits Heterogeneous Phenotypes and Resistance to Common Antineoplastic Drugs.
    Lin CA; Yu SL; Chen HY; Chen HW; Lin SU; Chang CC; Yu CJ; Yang PC; Ho CC
    J Thorac Oncol; 2019 Mar; 14(3):513-526. PubMed ID: 30521971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case report: EGFR-mutant lung adenocarcinoma with the TP53 and RB1 mutations showed resistance to TKI therapy.
    Lu Y; Li Z; Zhu H; Zhao J; Xu M; Gu W
    Ann Palliat Med; 2021 Dec; 10(12):12886-12893. PubMed ID: 35016432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small Cell Lung Cancer Derived from Adenocarcinoma with Mutant Epidermal Growth Factor Receptor Provides a Signature of Transcriptional Alteration in Tumor Cells.
    Tenjin Y; Nakamura K; Ishizuka S; Saruwatari K; Sato R; Tomita Y; Saeki S; Ichiyasu H; Fujii K; Ito T; Sakagami T
    Intern Med; 2019 Nov; 58(22):3261-3265. PubMed ID: 31292388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small-cell lung cancer transformation from EGFR-mutant adenocarcinoma after EGFR-TKIs resistance: A case report.
    Jiang Y; Shou L; Guo Q; Bao Y; Xu X; An S; Lu J
    Medicine (Baltimore); 2021 Aug; 100(32):e26911. PubMed ID: 34397927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case report: small cell transformation and metastasis to the breast in a patient with lung adenocarcinoma following maintenance treatment with epidermal growth factor receptor tyrosine kinase inhibitors.
    Lin Q; Cai GP; Yang KY; Yang L; Chen CS; Li YP
    BMC Cancer; 2016 Aug; 16():593. PubMed ID: 27488410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T790M mutation positive squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma after low dose erlotinib: A case report and literature review.
    Kusaba Y; Takeda Y; Abe S; Tsukada A; Naka G
    Medicine (Baltimore); 2022 Aug; 101(32):e29682. PubMed ID: 35960133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.
    Minari R; Bordi P; Del Re M; Facchinetti F; Mazzoni F; Barbieri F; Camerini A; Comin CE; Gnetti L; Azzoni C; Nizzoli R; Bortesi B; Rofi E; Petreni P; Campanini N; Rossi G; Danesi R; Tiseo M
    Lung Cancer; 2018 Jan; 115():21-27. PubMed ID: 29290257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
    Niederst MJ; Sequist LV; Poirier JT; Mermel CH; Lockerman EL; Garcia AR; Katayama R; Costa C; Ross KN; Moran T; Howe E; Fulton LE; Mulvey HE; Bernardo LA; Mohamoud F; Miyoshi N; VanderLaan PA; Costa DB; Jänne PA; Borger DR; Ramaswamy S; Shioda T; Iafrate AJ; Getz G; Rudin CM; Mino-Kenudson M; Engelman JA
    Nat Commun; 2015 Mar; 6():6377. PubMed ID: 25758528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.